EUVIMEDEUVIMED entdecken
Crossref

Balancing Progress and Precautions with Emerging Biotechnologies: Evaluating the Process of Gene Therapy Research Becoming “Normal”

Stephanie Solomon Cargill iD

Journal of Law, Medicine & Ethics · 2026

DOI: 10.1017/jme.2025.10210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, 2026. Verfasst von Stephanie Solomon Cargill. Beteiligte Einrichtung: Alden March Bioethics Institute, Albany Medical Collegehttps://ror.org/03g66yt05, United States. Hauptthemen laut MEDLINE: Genetic Therapy, Biotechnology, Biomedical Research, Guidelines as Topic. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, we have seen an immense expansion in recombinant DNA, especially in its use in gene therapy applications. Throughout its history, the United States set up several mechanisms of national safety and ethical oversight for rDNA to ensure that we proceeded with its use appropriately. As our knowledge and experience with it grew, there has been increasing pressure to decrease the oversight and monitoring requirements for its use. In 2019, the National Institutes of Health amended the NIH Guidelines for Research Involving Recombinant DNA Molecules eliminated three national mechanisms for guidance, monitoring, and review of this biotechnology. Four years later, we revisit these changes and their implications for a current emerging biotechnology: xenotransplantation. By better understanding the motivations for these mechanisms and analyzing the test case, we argue that these changes have worrisome implications for our ethical oversight of emerging biotechnologies both in the realm of gene transfer technologies and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyBiotechnologyBiomedical ResearchGuidelines as TopicHumansNational Institutes of Health (U.S.)United StatesDNA, RecombinantGene Transfer TechniquesEthics, ResearchEthics Committees, ResearchTransplantation, Heterologous

Stichwörter der Autor:innen

BiotechnologiesGene therapyInstitutional Biosafety BoardsInstitutional Review BoardsRecombinant DNA Advisory Committee (RAC)

Substanzen

DNA, Recombinant

Autor:innen und Institutionen

  • Alden March Bioethics Institute, Albany Medical Collegehttps://ror.org/03g66yt05, United States.

ORCID-Profile: Stephanie Solomon Cargill

Zitieren

APA

Cargill, S. S. (2026). Balancing Progress and Precautions with Emerging Biotechnologies: Evaluating the Process of Gene Therapy Research Becoming “Normal”. Journal of Law, Medicine & Ethics. https://doi.org/10.1017/jme.2025.10210

Vancouver

Cargill SS. Balancing Progress and Precautions with Emerging Biotechnologies: Evaluating the Process of Gene Therapy Research Becoming “Normal”. Journal of Law, Medicine & Ethics. 2026. doi:10.1017/jme.2025.10210

BibTeX
@article{Cargill2026,
  author = {Cargill, Stephanie Solomon},
  title = {Balancing Progress and Precautions with Emerging Biotechnologies: Evaluating the Process of Gene Therapy Research Becoming “Normal”},
  journal = {Journal of Law, Medicine & Ethics},
  year = {2026},
  doi = {10.1017/jme.2025.10210}
}
Kostenlos starten →